title: A functional model of hepatocyte transplantation for in vivo immunologic studies.
abstract: BACKGROUND
  Previous studies to determine the significant donor and host factors which contribute to immune responses to allogeneic hepatocytes have been pursued with in vitro and in vivo studies. However, in order to further characterize in vivo host immune responses to transplanted hepatocytes in conjunction with their consequences upon allograft survival, a functional model of hepatocyte transplantation in which the function and survival of transplanted hepatocytes could be serially assessed was pursued.
  
  
  METHODS
  A transgenic mouse line expressing the human alpha1-antitrypsin (hA1AT) gene was developed in an FVB/N (H2q) mouse (hA1AT-FVB/N). Hepatocytes from these "donor" transgenic mice were transplanted into host mice by intrasplenic injection, and subsequent survival of the transgenic hepatocytes was determined by assay for the secreted hA1AT protein in host serum by enzyme-linked immunosorbent assay.
  
  
  RESULTS
  Transplantation of transgenic "donor" hepatocytes (hA1AT-FVB/N) into (a) syngeneic FVB/N (H2q), (b) allogeneic immunoincompetent C57BL/6.SCID (H2b), or (c) allogeneic T cell-deficient (outbred) hosts resulted in long-term survival (> 16 weeks) of hepatocytes. Transplantation of allogeneic hepatocytes (hA1AT-FVB/N, H2q) into C57BL/6 (H2b), C3H (H2k), or BALB/c (H2d) hosts resulted in loss of hA1AT in host serum by day 10 after transplant. Likewise, transplantation of allogeneic hepatocytes into hosts deficient in B cells, CD8+ T cells, or CD4+ T cells resulted in loss of hA1AT by day 10 after transplant.
  
  
  CONCLUSIONS
  This functional model of hepatocyte transplantation is validated for the study of host immune responses to hepatocellular grafts and to assess efficacy of strategies designed to alter these in vivo immune responses. The immunologic rejection of allogeneic hepatocytes appears to be T cell-mediated.
authors.affiliation: Department of Surgery, The Ohio State University, Columbus 43210, USA.
authors.forename: G L
authors.initials: GL
authors.lastname: Bumgardner
authors.forename: M
authors.initials: M
authors.lastname: Heininger
authors.forename: J
authors.initials: J
authors.lastname: Li
authors.forename: D
authors.initials: D
authors.lastname: Xia
authors.forename: J
authors.initials: J
authors.lastname: Parker-Thornburg
authors.forename: R M
authors.initials: RM
authors.lastname: Ferguson
authors.forename: C G
authors.initials: CG
authors.lastname: Orosz
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D006085:Graft Survival; D006207:Half-Life; D006801:Humans; D007124:Immunoenzyme Techniques; D016031:Liver Transplantation / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D016133:Polymerase Chain Reaction; D013156:Splenectomy; D000515:alpha 1-Antitrypsin / Q000235:genetics / Q000493:pharmacokinetics
chemical_list: D000515:alpha 1-Antitrypsin